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Objectives: Clinicians treating patients with advanced NSCLC have a range of 
options for care. The objective of this study was to develop a cost-effectiveness 
(CE) model to compare induction-maintenance sequences approved for use in the 
U.S. for the treatment of advanced non-squamous NSCLC given the absence of 
direct head-to-head trials. MethOds: The modelled regimens that were licensed 
in the United States included pemetrexed+cisplatin followed by (→ ) pemetrexed; 
pemetrexed+cisplatin→ best supportive care (BSC); gemcitabine+cisplatin→ BSC; 
gemcitabine+cisplatin→ erlotinib; gemcitabine+cisplatin→ pemetrexed; and pac
litaxel+carboplatin+bevacizumab→ bevacizumab. Treatment effects of induction 
and maintenance on survival endpoints were obtained using data from a previ-
ous network meta-analysis. Decision analytic modelling was used to synthesise 
the treatment effect and baseline risk estimates for the induction and mainte-
nance treatment sequences. The CE model was structured using an area-under-
the-curve approach, costs and benefits were discounted at 3.5% per annum, 
and probabilistic and one-way sensitivity analyses were conducted to evaluate 
model parameters. Results: All active maintenance therapy-containing regi-
mens, with the exception of gemcitabine+cisplatin→ erlotinib, were more costly 
than induction-only regimens. Gemcitabine+cisplatin→ BSC was the baseline 
comparator and established the cost effective threshold range of $0 to $121,425. 
The respective incremental costs per life year (LY) were $121,425, $148,994, and 
$191,270 for gemcitabine+cisplatin→ erlotinib versus gemcitabine+cisplatin→ BSC, 
pemetrexed+cisplatin→ BSC versus gemcitabine+cisplatin→ erlotinib, and 
pemetrexed+cisplatin→ pemetrexed versus pemetrexed+cisplatin→ BSC. 
Other regimens were dominated (paclitaxel+carboplatin+bevacizumab→ beva-
cizumab) or extendedly dominated (gemcitabine+cisplatin→ pemetrexed). 
Sensitivity analyses demonstrated that efficacy data and the method of extrap-
olating survival had the greatest impact on the cost-effectiveness results. 
For non-dominated regimens, the cost-effectiveness acceptability frontier 
showed that gemcitabine+cisplatin→ BSC, pemetrexed+cisplatin→ BSC, and 
pemetrexed+cisplatin→ pemetrexed had the greatest probabilities of cost-effec-
tiveness over the following threshold ranges: $0-$124,000/LY; $124,000-$220,000/
LY; and above $220,000/LY, respectively. cOnclusiOns: Depending on the specific 
cost-effectiveness threshold used by a decision maker, the cost-effective treatment 
sequence will be gemcitabine+cisplatin→ BSC, gemcitabine+cisplatin→ erlotinib, 
pemetrexed+cisplatin→ BSC, or pemetrexed+cisplatin→ pemetrexed. Paclitaxel+c
arboplatin+bevacizumab→ bevacizumab and gemcitabine+cisplatin→ pemetrexed 
were dominated or extendedly dominated and thus not cost-effective when rank-
ing these comparators.
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Objectives: As antiretroviral therapy is scaled up in Africa, HIV-positive women 
are increasingly likely to die from cervical cancer, a leading cause of cancer death. 
Effective screens for cervical cancer exist including Papanicolaou smear (Pap), 
visual inspection of the cervix with acetic acid (VIA), and human papillomavirus 
testing (HPV). Our objective was to prospectively assess cost-effectiveness of cervi-
cal cancer screening methods for HIV-positive women. MethOds: The analysis 
was based on data from 500 HIV-positive women who underwent VIA, Pap, HPV, 
and gold-standard colposcopy-directed biopsy in Nairobi, Kenya. A Markov model 
projected life expectancy and costs for six cervical screening strategies: Pap; VIA; 
HPV; testing positive for both VIA+Pap, Pap+HPV, VIA+HPV. Cost-effectiveness was 
calculated for overall population and by CD4 count. Strategies were compared 
using an incremental cost-effectiveness ratio (ICER)—the additional cost per life 
year (LY) gained. Impact of parameter uncertainty was addressed using univariate 
and probabilistic multivariate sensitivity analysis. Results: VIA had lowest cost 
and highest life expectancy ($331, 17.2 LYs), followed by HPV ($569, 17.1 LYs), Pap 
($622, 17.1 LYs), HPV+Pap ($836, 17.0 LYs), VIA+HPV ($857, 17.0 LYs), and VIA+Pap 
($897, 17.0 LYs). CD4 level did not affect this rank order, though VIA at low CD4 
showed the lowest cost ($111, 15.3 LY), while VIA at high CD4 produced most health 
gains ($285, 19.9 LY) [ICER: $37/LY]. Costs were sensitive to prevalence of cancer, 
sensitivity, age, and cost of cancer. Life expectancy was sensitive to age at screen-
ing. Results were robust to probabilistic sensitivity analysis. cOnclusiOns: VIA 
is projected to be the most cost-effective screening strategy for cervical cancer 
among HIV-positive women. This is due to its high sensitivity, low screening cost, 
low risk treatment, and high cervical cancer cost. Screening women with high 
CD4 is particularly cost-effective. VIA should be implemented among HIV-positive 
women in low-income settings.
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Objectives: 10-20% of patients diagnosed with prostate cancer progress to meta-
static castration-resistant prostate cancer (mCRPC). Recently, four novel therapies 
have been introduced for the treatment of mCRPC; of these, abiraterone and sip-
uleucel-T have been studied in the asymptomatic, pre-docetaxel population. Both 
have shown clinical benefits compared to placebo. This study evaluated the cost-
effectiveness of abiraterone acetate and sipuleucel-T compared to prednisone in 
asymptomatic, pre-docetaxel mCRPC from a US societal perspective. MethOds: 
A Markov model was constructed to simulate stable disease, progressed disease, 
and death. Survival and event rates were derived from published clinical trial data. 
Costs were derived from the literature and government reimbursement schedules. 
Utilities were derived from the literature. Outcomes were measured as average 
cost-effectiveness ratios (ACER), incremental cost-effectiveness ratios (ICER), and 
net monetary benefits (NMB). One-way and probabilistic sensitivity analyses were 
ing imatinib. MethOds: A retrospective study spanning July 2004-December 2011 
analyzed data from 3 large integrated claims databases. Patients with a GIST-related 
ICD-9-CM code (151.0-154.0, 158.0, 159.0, 159.8, 159.9, 171.0, 171.4-171.9, 239.0) receiv-
ing imatinib were eligible if they (1) had a minimum eligibility of 6 months prior 
and 12 months following their first GIST diagnosis and (2) no previous diagnosis of 
cancer. Patients were divided into 2 cohorts: surgical (S) and non-surgical (NS). ST 
treatment patterns and corresponding GIST-related average monthly costs were evalu-
ated. Results: There were 57 (24 S, 33 NS), 98 (62 S, 36 NS), and 276 (156 S, 120 NS) 
patients in each of the 3 databases meeting all inclusion criteria, respectively. Average 
monthly cost of first-line therapy ranged from $26,465 to $78,081, with variation being 
driven by length of treatment. 42%-56% of NS and 41%-58% of S patients received 
second-line therapy, costing an average of $3,197-$5,334 per month. The majority of 
patients in each database received imatinib mono- or combination therapy as second-
line treatment (60%-74% NS; 74%-86% S). Third-line therapy was received by 13%-33% of 
NS and 19%-30% of S patients, with an average cost per month ranging from $2,354 to 
$30,993. Imatinib was also received third-line by the majority of the patients in 2 data-
bases (59%-67% NS, 60-75% S); sunitinib was most commonly utilized (43% NS, 58% S) in 
the third database. cOnclusiOns: Over half of all patients receiving imatinib undergo 
surgery. Among both S and NS patients, second-line therapy for GIST was dominated 
by imatinib, while third-line therapy was dominated by imatinib or sunitinib.
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hosPitAl Costs of Adverse eveNts iN PAtieNts With MetAstAtiC 
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Objectives: This study aimed to elucidate the hospitalization costs of adverse 
events (AEs) commonly associated with treatments for metastatic mela-
noma. MethOds: Based on current drug labels and published clinical studies for 
the treatments of metastatic melanoma, 23 serious adverse events were identified. 
Length of stay (days) and hospitalization costs (2013 US $) for these 23 events (identi-
fied by primary discharge diagnoses) were examined using a large national claims 
database, in which patients with metastatic melanoma were identified from July 
2004 to November 2012. All analyses are presented descriptively. Results: There 
were 2998 patients with metastatic melanoma: most were male (59.5%) and the 
mean age was 55.8 years old. Hospitalizations due to acute myocardial infarction 
and sepsis incurred the longest median length of stay (9 and 6 days, respectively), 
followed by acidosis (5.5 days), acute kidney failure, pneumonitis, neuropathy, 
thrombocytopenia, and oliguria/anuria (all had 5 days). The highest inpatient cost 
per event was for acute myocardial infarction (mean $45,971 and median $53,747), 
followed by sepsis ($34,351 and $22,838), coma ($30,943 and $23,149), acute kidney 
failure ($30,485 and $19,972), neuropathy ($28,977 and $12,034), and pneumonitis 
($27,669 and $21,011). Colitis/diarrhea, cutaneous squamous cell carcinoma, throm-
bocytopenia, hyponatremia, oliguria/anuria, hypertension, anemia, and elevated 
liver enzymes were associated with mean costs per hospitalization ranging from 
$26,234 to $18,676. In contrast, the lower inpatient cost per event was for cellulitis 
(mean $16,828 and median $12,045), fever ($15,078 and $13,650), rash ($14,432 and 
$12,086), and nausea ($13,715 and $10,892). cOnclusiOns: Hospital costs for the 
management of adverse events vary greatly. This study provides source data for 
economic evaluation of treatments for metastatic melanoma.
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Objectives: A high percentage of patients recalled after screening mammography do 
not have cancer. The goal of this study is to describe the prevalence and cost to health 
plans of patient recall in the 6 months following screening mammography. MethOds: 
The Truven Health MarketScan Commercial and Medicare Supplemental Databases were 
used to identify women aged 40-75 years undergoing screening mammography (index 
event) in 2010-2012. Women were required to have 12 months pre- and 6 months 
post-index continuous enrollment. Women with mammography or a breast cancer 
diagnosis in the 12 month pre-index period were excluded. Recall was defined as 
receipt of a second breast-related imaging procedure, coinciding with an abnormal 
mammogram diagnosis code or a breast-related diagnosis in the 6 months following 
the index screen. Payer cost per recall (2012 US$) was the sum of breast-related imagin-
ing procedures and associated visit costs in the 6 months post-index, excluding patient 
payments. Breast cancer treatment costs were not included in recall costs. Results: 
Of the 1,553,044 women who met the study inclusion criteria, 246,233 (15.9%) had 
an abnormal mammogram or related diagnosis code and had a subsequent imaging 
procedure in the 6 months post-index. The average cost per patient recalled was $1,082 
in the 6 months following screening mammography. The majority of recalls included 
diagnostic mammography (71.8%) or ultrasound (51.9%), which accounted for 12% and 
9% of recall costs, respectively. Office visits and pathology services accounted for 42% 
of recall costs. Biopsy was performed in 19.3% of recalled patients and accounted for 
27% of recall costs. MRI, fine needle aspiration, and ductogram accounted for < 5% of 
recall costs. cOnclusiOns: Approximately one-in-six women undergoing screening 
mammography were recalled for further imaging within 6 months, with an average 
cost to health plans of $1,082 per patient. Improving breast cancer screening with a 
more accurate mammogram may significantly reduce payer costs.
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(dacarbazine and vemurafenib) in Canada from a societal perspective. MethOds: 
A partitioned survival analysis model with 3 health states (pre-progression, 
post-progression, dead) estimated direct and indirect costs and quality-adjusted 
life-years (QALYs) for patients with BRAF V600+ advanced or metastatic melanoma 
receiving 1L treatment with trametinib, dacarbazine, or vemurafenib. Clinical 
inputs for trametinib and dacarbazine were from the METRIC trial (in the 1L 
chemotherapy group, 87%, 6% and 6% of patients received dacarbazine, paclitaxel, 
and no drug, respectively). Clinical inputs for vemurafenib were from an indirect 
treatment comparison of data from the METRIC and BRIM-3 studies. Resource 
utilization data were derived from physician survey results, drug costs from the 
manufacturers’ price and Quebéc medications lists, and other costs from pub-
lished sources. Consistent with a prior evaluation of vemurafenib, a 5-year time 
horizon was used. Costs and QALYs were discounted at 5% annually. Results: 
QALYs gained with trametinib were 0.4160 vs. dacarbazine and 0.1241 vs. vemu-
rafenib. Compared with dacarbazine, incremental costs for trametinib were 
$61,226, resulting in a cost of $147,177 per QALY gained. Compared to vemurafenib, 
trametinib yielded a cost savings of $26,553 and was therefore dominant (less 
costly, more effective). Probabilistic sensitivity analyses showed a 14% and 98% 
probability of trametinib being cost effective vs. dacarbazine and vemurafenib, 
respectively, based on a $100,000/QALY threshold. cOnclusiOns: In patients with 
BRAF V600+ advanced or metastatic melanoma, 1L treatment with trametinib may 
not be cost-effective vs. dacarbazine but may be cost-effective vs. vemurafenib. 
There is uncertainty in the vemurafenib comparison given the lack of head-to-
head data.
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Cost-effeCtiveNess of ArseNiC trioxide + All-trANs retiNoiC 
ACid CoMPAred With All-trANs retiNoiC ACid + idArubiCiN iN the 
treAtMeNt of NeWly diAgNosed ACute ProMyeloCytiC lyMPhoMA 
leuKeMiA iN CANAdA
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Objectives: Acute promyelocytic leukemia (APL) constitutes a distinct and rare 
variant of acute myeloid leukemia and is characterized by a high early mortality 
rate. Although current treatments (all-trans retinoic acid (ATRA), anthracyclines, 
including idarubicin, IDA, and conventional chemotherapy) are associated with high 
remission rates, cytotoxic effects of chemotherapy treatment are still a concern in 
the management of newly diagnosed APL. The objective of this study was to assess, 
from a Canadian perspective, the economic impact of arsenic trioxide (ATO) +ATRA 
compared to ATRA+IDA in the treatment of newly diagnosed APL. MethOds: The 
cost-effectiveness of ATO+ATRA compared to ATRA+IDA in the treatment of newly 
diagnosed APL was assessed over a lifetime horizon using a time-dependent Markov 
model. The model comprises four health states: complete remission, treatment 
failure or relapse, post-failure, and death. The length of each Markov cycle was 
one month for the first 48 months and one year thereafter. All patients started in 
the complete remission state and could move to other health states thereafter, 
according to the respective efficacy of each treatment. The model also takes into 
account the incidence of adverse events reported in a head-to-head trial. Utility or 
disutility values associated with each health state and adverse events were used 
to estimate the number of QALYs associated with each treatment. Analyses were 
conducted from both a Canadian Ministry of Health (MoH) and a societal perspec-
tive. Results: Compared with ATRA+IDA, ATRA+ATO is associated with ICERs of 
$84,092/QALY and $80,946/QALY, from a MoH and societal perspective respectively. 
Results of the probabilistic sensitivity analysis indicated that the ICER remains 
below $100,000 in 99.82% and 99.98% of the simulations from a MoH and a societal 
perspective respectively. cOnclusiOns: This economic evaluation suggests that 
ATO+ATRA can be considered a cost-effective option for the first-line treatment of 
newly diagnosed APL patients.
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Adam V.1, Lu Y.1, Barkun A.2, Martel M.2, Moses P.3
1McGill University, Montreal, QC, Canada, 2McGill University Health Center, Montreal, QC, 
Canada, 3University of Vermont, Burlington, VT, USA
Objectives: Partially covered self expandable metal stents (SEMS) and polyethyl-
ene stents (PES) are commonly used for distal malignant biliary obstruction. SEMS 
are more efficacious yet expensive than PES. The cost-effectiveness of both stents 
using contemporary estimates was assessed. MethOds: A decision tree compar-
ing initial palliative placement of PES versus SEMS was constructed for patients 
with distal malignant biliary obstruction requiring palliation with one-year fol-
low-up. Patients underwent an endoscopic retrograde cholangiopancreatography 
(ERCP) to insert the initial stent, and were followed by a gastroenterologist every 
3 months. If the insertion failed, a percutaneous transhepatic cholangiogram was 
performed. If stent occlusion occurred, a PES was then inserted at repeat ERCP, either 
in an outpatient setting, or after admission to hospital if cholangitis was present. 
Effectiveness was expressed as the likelihood of no occlusion. Costs were measured 
in US dollars. Probabilities were issued from a recent published randomized clini-
cal trial. Results: A PES-first strategy was dominated by a SEMS-first approach. 
The average cost was $6,541 USD for initial SEMS and $19,054 USD for initial PES, 
associated with respective effectiveness probabilities of 65.6% and 13.9% (likeli-
hood of experiencing no occlusion over 12 months). Sensitivity analyses confirmed 
the robustness of these results. They are however limited by the randomized trial 
where the probabilities were derived from, with regards to sample size and gener-
alizability. cOnclusiOns: At the time of initial endoscopic drainage for patients 
with malignant biliary obstruction undergoing palliative stenting, an initial SEMS 
approach is both more effective and less costly than a PES-first strategy, regardless 
of anticipated survival or cost setting
conducted to test the robustness of the model. Results: The base-case ACER 
was $114k/QALY for abiraterone, $85k/QALY for sipuleucel-T, and $31k/QALY for 
prednisone. The base-case ICER was $389k/QALY for abiraterone, $547k/QALY for 
sipuleucel-T. Prednisone dominates both abiraterone and sipuleucel-T in terms 
of NMB at WTP thresholds of < $400k. At WTP thresholds of < $275k, sipuleucel-
T dominates abiraterone. One-way sensitivity analyses revealed that the model 
was most sensitive to overall survival and utility inputs. Probabilistic sensitivity 
analyses showed abiraterone to be cost-effective > 50% of the time at a WTP 
of > $400k, while sipuleucel-T was cost-effective > 50% of the time at a WTP of 
> $270k. cOnclusiOns: Neither abiraterone nor sipuleucel-T was found to be 
cost-effective compared to prednisone in the treatment of asymptomatic, pre-
docetaxel mCRPC.
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A Novel ColoreCtAl CANCer Model With sessile serrAted AdeNoMA 
PAthWAy to evAluAte the Cost-effeCtiveNess of vArious sCreeNiNg 
strAtegies
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Objectives: Sessile serrated adenoma (SSA) was recently recognized as a sepa-
rate pathway that accounts for 10-35% of colorectal cancers (CRCs). Current CRC 
screening tests exhibit inferior performance detecting SSAs as compared to other 
lesion types. Most existing CRC models do not include the SSA pathway; thus, the 
cost effectiveness of CRC screening in the face of inferior SSA detection remains 
uncertain. We developed a novel CRC model that incorporates the SSA pathway 
to evaluate the cost-effectiveness of various screening strategies. MethOds: We 
modeled CRC progression in a simulated cohort of 100,000 individuals from age 
50 to 75 that were representative of the general US population. We investigated 
several CRC screening strategies within this cohort: colonoscopy every ten years 
(Q10 COLO); fecal immunochemical testing (FIT) every one, two, or three years (Q1 
FIT, Q2 FIT or Q3 FIT); and a hybrid strategy of colonoscopy every ten years with 
FIT one, two, or three years after negative colonoscopy (COLO/FIT 1, COLO/FIT 2, 
COLO/FIT 3). The primary outcomes were cancer incidence, medical cost, quality-
adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) per QALY. 
We assumed full screening compliance. All economic outcomes were discounted 
at 3% per year. Results: All screening strategies were cost saving compared to 
no screening. The COLO/FIT 2 hybrid strategy reduced cancer incidence the most 
(59% compared to no screening) and gained the most QALYs compared to no 
screening (15,200 QALYs for every 100,000 people). Compared with the standard 
Q10 COLO strategy, COLO/FIT hybrid strategies produced ICERs of approximately 
$3,300 per QALY. cOnclusiOns: Despite the comparatively poor performance 
of colonoscopy and FIT in detecting SSAs, our simulation results suggested that 
CRC screening would save costs and increase QALYs. Hybrid screening strate-
gies with colonoscopy and FIT were cost-effective compared to screening with 
colonoscopy alone.
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CoMPAred With fludArAbiNe-rituxiMAb treAtMeNt, iN PAtieNts With 
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Objectives: To assess the cost-effectiveness of Bendamustine-Rituximab (BR) 
compared with Fludarabine-Rituximab (FR) treatment, in patients with Indolent 
Non-Hodgkin’s Lymphoma (INHL) that have progressed during or within six 
months of treatment with Rituximab or a Rituximab-containing Regimen in 
Panamá. MethOds: A three-health state cohort simulation Markov Model (progres-
sion-free, progressive disease, and death) was developed, based on time-dependent 
progression-free survival and overall survival data. The time frame was lifetime 
(35 years). The perspective was that of the National Health System of Panamá. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs), Life Years 
(LYs), and Progression-free Life Years (PFLYs). Resource consumption for health 
states was elicited with the support of Latin American hematologists. Utilities for 
health states and disutility for adverse reactions were taken from published stud-
ies. All costs and Incremental Cost Effectiveness Ratios (ICERs) are presented in 
United States Dollars. Costs and outcomes were discounted at 3%. One way and 
probabilistic sensitivity (PSA) analysis were performed. Results: BR resulted in 
4,641 QALYs/ 6,432 LYs/ and 3,564 PFLYs, per patient, respectively. FR resulted in 3,557 
QALYs/5,138 LYs and 2,047 PFLYs, per patient, respectively. Total costs were: 140.768 
for BR and 125.097 for FR. ICERs were: 14.468 per QALY gained, 12.114 per LY gained 
and 10.331 per PFLY gained. In all outcomes, results were sensitive to Hazard Ratio of 
overall survival. According to the PSA, with QALYs as outcome, BR had a probability 
of 39% of being cost effective when considering the threshold of 3 times the Gross 
Domestic Product per capita (GDPPC) of Panamá (28.602). cOnclusiOns: BR can 
be considered cost-effective compared with FR in the study population (INHL) in 
Panamá, according to the classification suggested by the World Health Organization 
[cost effective between 1 and 3 GDPPC (9534-28602)].
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Objectives: The METRIC trial demonstrated clinical benefits of trametinib vs. 
chemotherapy (dacarbazine or paclitaxel) in patients with BRAF V600+ advanced or 
metastatic melanoma overall, and in a subgroup receiving 1L treatment. We evalu-
ated the cost-effectiveness of trametinib as a 1L treatment vs. approved treatments 
